鏈接全球制藥生態(tài) 共筑健康未來

Connecting the Global Pharmaceutical

Ecosystem, Building a Healthier Future Together

海南中和藥業(yè)閃耀 2025 德國(guó)法蘭克福 CPHI 原料藥展

Hainan Zhonghe Pharmaceutical Shines at CPHI Frankfurt 2025

2025年10月28日至30日，全球制藥行業(yè)的年度盛會(huì) —— 世界制藥原料展覽會(huì)（CPHI Frankfurt 2025）在德國(guó)法蘭克福展覽中心盛大落幕。作為全球規(guī)模最大、影響力最廣的制藥專業(yè)展會(huì)，本屆盛會(huì)匯聚了來自 150 多個(gè)國(guó)家和地區(qū)的 2500 余家參展商及 45000 余名專業(yè)觀眾，成為洞察行業(yè)趨勢(shì)、鏈接全球資源的核心樞紐。

From October 28 to 30, 2025, the world’s leading pharmaceutical event — CPHI Frankfurt 2025 — successfully concluded at Messe Frankfurt, Germany. As the largest and most influential pharmaceutical exhibition globally, this year’s event brought together over 2,500 exhibitors and 45,000 professional visitors from more than 150 countries and regions, serving as a central hub for industry insights and global collaboration.

作為中國(guó)多肽藥物研發(fā)與生產(chǎn)的領(lǐng)軍企業(yè)，海南中和藥業(yè)股份有限公司（以下簡(jiǎn)稱“海南中和藥業(yè)”）攜其領(lǐng)先的多肽產(chǎn)品線及國(guó)際化服務(wù)方案盛裝出席，與全球業(yè)界伙伴進(jìn)行了深度交流，充分展示了其在多肽領(lǐng)域的生產(chǎn)能力與國(guó)際化戰(zhàn)略布局。

As a leading enterprise in peptide drug research, development, and manufacturing in China, Hainan Zhonghe Pharmaceutical Co., Ltd. made a grand appearance at the event, showcasing its cutting-edge peptide product portfolio and comprehensive international service solutions. The company engaged in in-depth exchanges with global industry partners, fully demonstrating its strong manufacturing capabilities and strategic international presence in the peptide field.

● 聚焦核心優(yōu)勢(shì)，展示多肽技術(shù)硬核實(shí)力

● Highlighting Core Strengths, Showcasing the Power of Peptide Innovation

本次展會(huì)，海南中和藥業(yè)重點(diǎn)展示了公司在免疫、腫瘤、肝病、急救、消化、泌尿、婦科圍產(chǎn)等領(lǐng)域的核心原料藥產(chǎn)品矩陣，以及原料制劑一體化的產(chǎn)業(yè)優(yōu)勢(shì)。公司憑借其在固相合成技術(shù)上的深厚積累，向國(guó)際客戶呈現(xiàn)了從克級(jí)到公斤級(jí)、從常規(guī)到復(fù)雜長(zhǎng)鏈多肽的穩(wěn)定、規(guī)?；a(chǎn)能力。

At this exhibition, Hainan Zhonghe Pharmaceutical focused on showcasing its core API product portfolio across key therapeutic areas including immunology, oncology, hepatology, emergency medicine, gastroenterology, urology, and obstetrics & gynecology, as well as its integrated advantages in both API and finished dosage manufacturing. Leveraging its deep expertise in solid-phase synthesis technology, the company demonstrated to international clients its stable and scalable production capabilities, ranging from gram to kilogram levels and covering both conventional and complex long-chain peptides.

展會(huì)期間，海南中和藥業(yè)的展臺(tái)吸引了大量專業(yè)訪客駐足咨詢與洽談，我們通過產(chǎn)品展板、技術(shù)手冊(cè)、現(xiàn)場(chǎng)答疑等多種形式全方面推廣我們的核心成果。公司的商務(wù)團(tuán)隊(duì)和技術(shù)專家與全球各地區(qū)的潛在客戶、合作伙伴就多肽藥物的研發(fā)趨勢(shì)、質(zhì)量管控、產(chǎn)能保障和法規(guī)事務(wù)等議題進(jìn)行了廣泛而深入的探討，并達(dá)成了多項(xiàng)初步合作意向。

During the exhibition, Hainan Zhonghe Pharmaceutical’s booth attracted a large number of professional visitors for consultations and business discussions. Through product displays, technical brochures, and on-site Q&A sessions, the company comprehensively showcased its core achievements and technological strengths. The business and technical teams engaged in extensive and in-depth exchanges with potential clients and partners from around the world on topics such as peptide drug R&D trends, quality management, production capacity assurance, and regulatory affairs, leading to the establishment of multiple preliminary cooperation intentions.

● 深化國(guó)際合作，共拓全球醫(yī)藥市場(chǎng)

● Forging International Collaborations to Explore Global Pharma Horizons

CPHI是全球制藥原料領(lǐng)域最重要的交流平臺(tái)。通過此次參展，我們不僅鞏固了與老客戶的信任關(guān)系，更結(jié)識(shí)了眾多志同道合的新伙伴。我們深切感受到全球市場(chǎng)對(duì)高質(zhì)量、高性價(jià)比多肽藥物日益增長(zhǎng)的需求。海南中和藥業(yè)將始終堅(jiān)持 “立足中國(guó)、服務(wù)全球” 的發(fā)展理念，持續(xù)完善產(chǎn)業(yè)鏈布局，強(qiáng)化研發(fā)創(chuàng)新投入，推動(dòng)產(chǎn)品與服務(wù)向更高質(zhì)量、更寬領(lǐng)域、更深層次發(fā)展。

CPHI is the world’s most important platform for exchanges in the pharmaceutical API sector. Through our participation in this year’s exhibition, we not only strengthened trust with existing clients but also connected with many like-minded new partners. We deeply felt the growing global demand for high-quality, cost-effective peptide drugs. Hainan Zhonghe Pharmaceutical will continue to uphold its development philosophy of “Rooted in China, Serving the World”, steadily optimizing its industrial chain layout, enhancing investment in R&D and innovation, and promoting its products and services toward higher quality, broader scope, and deeper impact.

此次法蘭克福之行，是海南中和藥業(yè)推進(jìn)國(guó)際化戰(zhàn)略的關(guān)鍵一步。通過面對(duì)面的交流，公司進(jìn)一步了解了國(guó)際市場(chǎng)的動(dòng)態(tài)與需求，也為未來拓展更廣闊的海外市場(chǎng)奠定了堅(jiān)實(shí)的基礎(chǔ)。

This trip to Frankfurt marked a key step in Hainan Zhonghe Pharmaceutical’s internationalization strategy. Through face-to-face exchanges, the company gained a deeper understanding of international market dynamics and needs, laying a solid foundation for expanding its presence in global markets.

關(guān)于海南中和藥業(yè)股份有限公司

About Hainan Zhonghe Pharmaceutical Co., Ltd.

海南中和藥業(yè)股份有限公司（以下簡(jiǎn)稱中和藥業(yè)）成立于1995年4月17日，是我國(guó)專業(yè)從事化學(xué)合成多肽藥物的研究和實(shí)現(xiàn)產(chǎn)業(yè)化的國(guó)家高新技術(shù)企業(yè)，中國(guó)國(guó)內(nèi)化學(xué)合成多肽類新藥“注射用胸腺五肽”就由中和藥業(yè)自行研發(fā)上市，并在2003年“非典”疫情中發(fā)揮了重大作用，被海南省人民政府予以嘉獎(jiǎng)。歷經(jīng)近30年的發(fā)展，公司產(chǎn)品已涵蓋免疫、腫瘤、肝病、心血管、內(nèi)分泌、婦科圍產(chǎn)等多個(gè)治療領(lǐng)域，并擁有多肽原料藥、化學(xué)原料藥及小容量注射劑（包括預(yù)灌封、卡式瓶）、凍干粉針劑、片劑、膠囊劑等多種劑型的生產(chǎn)能力，產(chǎn)品已成功出口韓國(guó)、烏茲別克斯坦、蒙古、巴基斯坦等多個(gè)國(guó)家和地區(qū)。

Hainan Zhonghe Pharmaceutical Co., Ltd. (hereinafter Zhonghe Pharmaceutical) was founded on April 17, 1995, and is a national high-tech enterprise in China specializing in the research and industrialization of chemically synthesized peptide drugs. The company independently developed and launched China’s first chemically synthesized peptide new drug, Thymopentin for Injection, which played a significant role during the SARS outbreak in 2003 and was recognized with an award by the Hainan Provincial Government. After nearly 30 years of development, Zhonghe Pharmaceutical’s products now cover multiple therapeutic areas, including immunology, oncology, hepatology, cardiovascular, endocrinology, and obstetrics & gynecology. The company has production capabilities for peptide APIs, chemical APIs, and various dosage forms, including small-volume injections (pre-filled and cartridge vials), lyophilized powders for injection, tablets, and capsules. Its products have been successfully exported to South Korea, Uzbekistan, Mongolia, Pakistan, and other countries and regions.

歡迎掃描二維碼，瀏覽我們的藥品、原料藥及化妝品產(chǎn)品目錄。

Scan the QR code to discover our range of pharmaceuticals, APIs, and cosmetics

孫經(jīng)理 Director Sun:18078993802(國(guó)內(nèi)) Domestic Department

唐經(jīng)理 Director Tang:13876688684(國(guó)內(nèi)) Domestic Department

TEL:0898-66802207(國(guó)際) International Department                    

E-mail: lizhongjing@zhonghe.cn(國(guó)際) International Department